1. Market Research
  2. > Business Services
  3. > Research and Development Market Trends
DNX-2401 (Tasadenoturev) - Emerging Drug Insight and Market Forecast – 2030

DNX-2401 (Tasadenoturev) - Emerging Drug Insight and Market Forecast – 2030

  • September 2020
  • 50 pages
  • ID: 5967845
  • Format: PDF
  • Delve Insight
Up to $1950 off Until Dec 10th 2020

Summary

Table of Contents

“DNX-2401 (Tasadenoturev) - Emerging Drug Insight and Market Forecast – 2030” the report provides comprehensive insights about an investigational product for Glioblastoma in 7 Major Markets. A detailed picture of the DNX-2401 (TASADENOTUREV) in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020–2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

Drug Summary
DNX-2401 is an oncolytic adenovirus engineered specifically to infect, replicate in, and kill cancer cells to elicit an immune response. Prior clinical studies have demonstrated that DNX-2401 was well tolerated and extended survival for patients with recurrent glioblastoma. DNX-2401 is currently being evaluated in several clinical trials, including a multicenter Phase 2 study evaluating DNX-2401 with pembrolizumab for adult patients with recurrent glioblastoma. DNX-2401 has been granted PRIME and Orphan designation by the EMA, and Fast Track and Orphan designation by the FDA.

Scope of the report
The report provides insights into:
• A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
• Elaborated details on regulatory milestones and other development activities have been provided in this report.
• The report also highlights the drug research and development activity details across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around DNX-2401 (Tasadenoturev).
• The report contains forecasted sales for DNX-2401 (Tasadenoturev) till 2030.
• Comprehensive coverage of the late-stage emerging therapies (Phase III) for Glioblastoma.
• The report also features the SWOT analysis with analyst insights and key findings of DNX-2401 (Tasadenoturev).

Methodology
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by our team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

DNX-2401 (Tasadenoturev) Analytical Perspective
• In-depth DNX-2401 (Tasadenoturev) Market Assessment
This report provides a detailed market assessment of DNX-2401 (Tasadenoturev) in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.

• DNX-2401 (Tasadenoturev) Clinical Assessment
The report provides the clinical trials information of DNX-2401 (Tasadenoturev) covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights
• In the coming years, the market scenario for Glioblastoma is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics are working to assess challenges and seek opportunities that could influence DNX-2401 (Tasadenoturev) dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• Other emerging products for Glioblastoma are giving market competition to DNX-2401 (Tasadenoturev) and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of DNX-2401 (Tasadenoturev).
• Our in-depth analysis of the forecasted sales data of DNX-2401 (Tasadenoturev) from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the DNX-2401 (Tasadenoturev).

Key Questions
• Which company is developing DNX-2401 (Tasadenoturev) along with the phase of the clinical study?
• What is the technology utilized in the development of DNX-2401 (Tasadenoturev)?
• What is the product type, route of administration and mechanism of action of DNX-2401 (Tasadenoturev)?
• What is the clinical trial status of the study and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the DNX-2401 (Tasadenoturev) development?
• What are the key designations that have been granted to DNX-2401 (Tasadenoturev)?
• What is the forecasted market scenario of DNX-2401 (Tasadenoturev)?
• What is the history of DNX-2401 (Tasadenoturev) and what is its future?
• What is the forecasted sales of DNX-2401 (Tasadenoturev) in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how these are giving competition to DNX-2401 (Tasadenoturev)?
• Which are the late-stage emerging therapies under development for the treatment of the PPD?

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
20% Off

($3250)

  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

BLU 782- Emerging Drug Insight and Market Forecast – 2030

  • $ 3250
  • September 2020
  • 50 pages

“BLU 782- Emerging Drug Insight and Market Forecast – 2030” the report provides comprehensive insights about an investigational product for Fibrodysplasia ossificans progressiva (FOP) in 7 Majo ...

  • Europe
  • Japan
  • Research And Development
  • Clinical Trial
  • Industry analysis
  • Health Expenditure

ref:plp2020

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on